Current treatment of atypical mycobacteriosis

Bibliography

• Wolinsky E. Nontuberculous mycobacteria and associated diseases. Am Rev Respir Dis 1979;119(1):107-59
   PubMedGoogle Scholar
• Griffith DE, Aksamit T, Brown-Elliot BA, An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007;175:367-416
   PubMed Web of Science ®Google Scholar
• Martin-Casabona N, Bahrmand AR, Bennedsen J, Nontuberculous mycobacteria: patterns of isolation. A multi-country retrospective survey. Int J Tuberc Lung Dis 2004;8(10):1186-93
   PubMedGoogle Scholar
• McIlleron H, Wash P, Burger A, Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohors of tuberculosis patients. Antimicrob Agents Chemother 2006;50(4):1170-7
   PubMed Web of Science ®Google Scholar
• Almeida D, Nuermberger E, Tasneen R, Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis. Antimicrob Agents Chemother 2009;53(10):4178-84
   PubMedGoogle Scholar
• Dooley K, Flexner C, Hackman J, Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations. Antimicrob Agents Chemother 2008;52(11):4037-42
   PubMedGoogle Scholar
• Nijland HM, Ruslami R, Suroto AJ, Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis. Clin Infect Dis 2007;45(8):1001-7
   PubMedGoogle Scholar
• Taki H, Ogawa K, Nakagawa T, Clinical analysis of drug interaction between rifampicin and clarithromycin which are used for treating pulmonary Mycobacterium avium complex infection. Kekkaku 2007;82(8):641-6
   PubMedGoogle Scholar
• Wallace RJ, Brown BA, Griffith DE, Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-M. intracellulare infection. J Infect Dis 1995;171(3):747-50
   PubMedGoogle Scholar
• Yamamoto F, Harada S, Mitsuyama T, Concentration of clarithromycin and 14-R-hydroxy-clarithromycin in plasma of patients with Mycobacterium avium complex infection, before and after the addition of rifampicin. Jpn J Antibiot 2004;57(1):124-33
   PubMedGoogle Scholar
• Ruslami R, Nijland HM, Alisjahbana B, Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients. Antimicrob Agents Chemother 2007;51(7):2456-1
   Google Scholar
• Martin-Casabona N, Bahrmand AR, Bennedsen J, Nontuberculous mycobacteria: patterns of isolation. A multi-country retrospective survey. Int J Tuberc Lung Dis 2004;8(10):1186-93
   PubMedGoogle Scholar
• Ben Salah I, Cayrou C, Raoult D, Drancourt M. Mycobacterium marseillense sp. nov., Mycobacterium timonense sp. nov. and Mycobacterium bouchedurhonense sp. nov., novel species in the Mycobacterium avium complex. Int J Syst Evol Microbiol 2009. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• van Ingen J, Boeree MJ, Kösters K, Proposal to elevate Mycobacterium avium complex ITS sequevar MAC-Q to Mycobacterium vulneris sp. nov. Int J Syst Evol Microbiol 2009. [Epub ahead of print]
   Google Scholar
• Tortoli E, Rindi L, Garcia MJ, Proposal to elevate the genetic variant MAC-A, included in the Mycobacterium avium complex, to species rank as Mycobacterium chimaera sp. nov. Int J Syst Evol Microbiol 2004;54(Pt 4):1277-85
   PubMedGoogle Scholar
• Kim RD, Greenberg DE, Ehrmantraut ME, Pulmonary nontuberculous mycobacterial disease. Prospective study of a distinct preexisting syndrome. Am J Respir Crit Care Med 2008;178:1066-74
   PubMed Web of Science ®Google Scholar
• Dailloux M, Abalain ML, Laurain C, Respiratory infections associated with nontuberculous mycobacteria in non-HIV patients. Eur Respir J 2006;28(6):1211-5
   PubMedGoogle Scholar
• Kim RD, Greenberg DE, Ehrmantraut ME, Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome. Am J Respir Crit Care Med 2008;178(10):1066-74
   PubMedGoogle Scholar
• Brettle RP. Mycobacterium avium intracellulare infection in patients with HIV or AIDS. J Antimicrob Chemother 1997;40:156-60
   PubMedGoogle Scholar
• Wolinsky E. Mycobacterial diseases other than tuberculosis. Clin Infect Dis 1992;15(1):1-10
   PubMedGoogle Scholar
• Hocqueloux L, Lesprit P, Herrmann JL, Pulmonary Mycobacterium avium complex disease without dissemination in HIV-infected patients. Chest 1998;113(2):542-8
   PubMedGoogle Scholar
• Escalonilla P, Esteban J, Soriano ML, Cutaneous manifestations of infection by nontuberculous mycobacteria. Clin Exp Dermatol 1998;23:214-21
   PubMed Web of Science ®Google Scholar
• van Ingen J, Bendien SA, de Lange WC, Clinical relevance of non-tuberculous mycobacteria isolated in the Nijmegen-Arnhem region, The Netherlands. Thorax 2009;64(6):502-6
   PubMedGoogle Scholar
• The Research Committee of the British Thoracic Society. First randomised trial of treatments for pulmonary disease caused by M. avium intracellulare, M. malmoense, and M. xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol. Thorax 2001;56:167-72
   PubMedGoogle Scholar
• Griffith DE. Therapy of nontuberculous mycobacterial disease. Curr Opin Infect Dis 2007;20(2):198-203
   PubMedGoogle Scholar
• Heginbothom ML. The relationship between the in vitro drug susceptibility of opportunist mycobacteria and their in vivo response to treatment. Int J Tuberc Lung Dis 2001;5(6):539-45
   PubMedGoogle Scholar
• NCCLS. Susceptibility testing of mycobacteria, nocardiae and other aerobic actinomycetes; approved standard. NCCLS document M24-A. 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898, USA: NCCLS; 2003
   Google Scholar
• Pierce M, Crampton S, Henry D, A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med 1996;335(6):384-91
   PubMedGoogle Scholar
• Havlir DV, Dubé MP, Sattler FR, Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group. N Engl J Med 1996;335(6):392-8
   PubMedGoogle Scholar
• Sendi PP, Craig BA, Meier G, Cost-effectiveness of azithromycin for preventing Mycobacterium avium complex infection in HIV-positive patients in the era of highly active antiretroviral therapy. The Swiss HIV Cohort Study. J Antimicrob Chemother 1999;44(6):811-7
   PubMedGoogle Scholar
• Phillips P, Chan K, Hogg R, Azithromycin prophylaxis for Mycobacterium avium complex during the era of highly active antiretroviral therapy: evaluation of a provincial program. Clin Infect Dis 2002;34(3):371-8
   PubMedGoogle Scholar
• Aberg JA, Wong MK, Flamm R, Presence of macrolide resistance in respiratory flora of HIV-Infected patients receiving either clarithromycin or azithromycin for Mycobacterium avium complex prophylaxis. HIV Clinical Trials 2001;2(6):453-9
   PubMedGoogle Scholar
• Rossi M, Flepp M, Telenti A, Disseminated M. avium complex infection in the Swiss HIV Cohort Study: declining incidence, improved prognosis and discontinuation of maintenance therapy. Swiss Med Wkly 2001;131(31-32):471-7
   PubMedGoogle Scholar
• El-Sadr WM, Burman WJ, Grant LB, Discontinuation of prophylaxis for Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy. Terry Beirn Community Programs for Clinical Research on AIDS. N Engl J Med 2000;342(15):1085-92
   PubMedGoogle Scholar
• Shafran SD, Mashinter LD, Phillips P, Successful discontinuation of therapy for disseminated Mycobacterium avium complex infection after effective antiretroviral therapy. Ann Intern Med 2002;137(9):734-7
   PubMedGoogle Scholar
• McGrath EE, McCabe J, Anderson PB, Guidelines on the diagnosis and treatment of pulmonary non-tuberculous mycobacteria infection. Int J Clin Pract 2008;62(12):1947-55
   PubMedGoogle Scholar
• Jenkins PA, Campbell IA, Banks J, Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy. Thorax 2008;63:627-34
   PubMed Web of Science ®Google Scholar
• Lam PK, Griffith DE, Aksamit TR, Factors related to response to intermittent treatment of Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2006;173(11):1283-9
   PubMedGoogle Scholar
• Griffith DE, Brown-Elliott BA, Langsjoen B, Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2006;174(8):928-34
   PubMedGoogle Scholar
• Kohno Y, Ohno H, Miyazaki Y, In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan. Antimicrob Agents Chemother 2007;51(11):4071-6
   PubMedGoogle Scholar
• Bermudez LE, Inderlied CB, Kolonoski P, Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium. Antimicrob Agents Chemother 2001;45(1):217-22
   PubMedGoogle Scholar
• Koh WJ, Kim YH, Kwon OJ, Surgical treatment of pulmonary diseases due to nontuberculous mycobacteria. J Korean Med Sci 2008;23(3):397-401
   PubMedGoogle Scholar
• García-García A, Gálvez J, de Julián-Ortiz JV, New agents active against Mycobacterium avium complex selected by molecular topology: a virtual screening method. J Antimicrob Chemother 2004;53(1):65-73
   PubMedGoogle Scholar
• Huitric E, Verhasselt P, Andries K, Hoffner SE. In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor. Antimicrob Agents Chemother 2007;51(11):4202-4
   PubMedGoogle Scholar
• Taillard C, Greub G, Weber R, Clinical implications of Mycobacterium kansasii species heterogeneity: Swiss National Survey. J Clin Microbiol 2003;41(3):1240-4
   PubMedGoogle Scholar
• Cattamanchi A, Nahid P, Marras TK, Detailed analysis of the radiographic presentation of Mycobacterium kansasii lung disease in patients with HIV infection. Chest 2008;133(4):875-80
   PubMedGoogle Scholar
• Tompkins JC, Witzig RS. Mycobacterium kansasii in HIV patients: clarithromycin and antiretroviral effects. Int J Tuberc Lung Dis 2007;11(3):331-7
   PubMedGoogle Scholar
• Nakamura T, Yamamura Y, Tsuruta T, Mycobacterium kansasii arthritis of the foot in a patient with systemic lupus erythematosus. Intern Med 2001;40(10):1045-9
   PubMedGoogle Scholar
• Bernard L, Vincent V, Lortholary O, Mycobacterium kansasii septic arthritis: French retrospective study of 5 years and review. Clin Infect Dis 1999;29(6):1455-60
   PubMedGoogle Scholar
• Neuberger A, Sprecher H, Oren I. Septic arthritis caused by Mycobacterium kansasii in a prosthetic knee joint. J Clin Microbiol 2006;44(7):2648-9
   PubMedGoogle Scholar
• Alcaide F, Calatayud L, Santín M, Martín R. Comparative in vitro activities of linezolid, telithromycin, clarithromycin, levofloxacin, moxifloxacin, and four conventional antimycobacterial drugs against Mycobacterium kansasii. Antimicrob Agents Chemother 2004;48(12):4562-5
   PubMedGoogle Scholar
• da Silva Telles MA, Chimara E, Ferrazoli L, Riley LW. Mycobacterium kansasii: antibiotic susceptibility and PCR-restriction analysis of clinical isolates. J Med Microbiol 2005;54(Pt 10):975-9
   PubMedGoogle Scholar
• Klein JL, Brown TJ, French GL. Rifampin resistance in Mycobacterium kansasii is associated with rpoB mutations. Antimicrob Agents Chemother 2001;45(11):3056-8
   PubMedGoogle Scholar
• Shitrit D, Baum GL, Priess R, Pulmonary Mycobacterium kansasii infection in Israel, 1999-2004: clinical features, drug susceptibility, and outcome. Chest 2006;129(3):771-6
   PubMedGoogle Scholar
• Cynamon MH, Elliott SA, DeStefano MS, Yeo AE. Activity of clarithromycin alone and in combination in a murine model of Mycobacterium kansasii infection. The J Antimicrob Chemother 2003;52(2):306-7
   PubMedGoogle Scholar
• Guna R, Muñoz C, Domínguez V, In vitro activity of linezolid, clarithromycin and moxifloxacin against clinical isolates of Mycobacterium kansasii. J Antimicrob Chemother 2005;55(6):950-3
   PubMedGoogle Scholar
• Brown-Elliott BA, Crist CJ, Mann LB, In vitro activity of linezolid against slowly growing nontuberculous Mycobacteria. Antimicrob Agents Chemother 2003;47(5):1736-8
   PubMedGoogle Scholar
• Jiva TM, Jacoby HM, Weymouth LA, Mycobacterium xenopi: innocent bystander or emerging pathogen? Clin Infect Dis 1997;24:226-32
   PubMed Web of Science ®Google Scholar
• van Ingen J, Boeree MJ, de Lange WC, Mycobacterium xenopi clinical relevance and determinants, the Netherlands. Emerg Infect Dis 2008;14(3):385-9
   PubMedGoogle Scholar
• Esteban J, Molleja A, Górgolas M, Fernández-Roblas R. Clinical significance of the isolation of Mycobacterium xenopi. Med Clín (Barc) 1999;113(1):38-9
   PubMedGoogle Scholar
• Katoch VM. Infections due to non-tuberculous mycobacteria (NTM). Indian J Med Res 2004;120:290-304
   PubMed Web of Science ®Google Scholar
• Manfredi R, Nanetti A, Morelli S, A decade surveillance study of Mycobacterium xenopi disease and antimicrobial susceptibility levels in a reference teaching hospital of northern Italy: HIV-associated versus non-HIV-associated infection. HIV Clin Trials 2004;5(4):206-15
   PubMedGoogle Scholar
• Juffermans NP, Verbon A, Danner SA, Mycobacterium xenopi in HIV-infected patients: an emerging pathogen. AIDS 1998;12:1661-6
   PubMed Web of Science ®Google Scholar
• Lounis N, Truffot-Pernot C, Bentoucha A, Efficacies of clarithromycin regimens against Mycobacterium xenopi in mice. Antimicrob Agents Chemother 2001;45(11):3229-30
   PubMedGoogle Scholar
• Butler WR, O'Connor SP, Yakrus MA, Mycobacterium celatum sp. nov. Int J Syst Bacteriol 1993;43:539-48
   PubMedGoogle Scholar
• Christiansen DC, Roberts GD, Patel R. Mycobacterium celatum, an emerging pathogen and cause of false positive amplified Mycobacterium tuberculosis direct test. Diagn Microbiol Infect Dis 2004;49:19-24
   PubMedGoogle Scholar
• Tortoli E, Piersimoni C, Bacosi D, Isolation of the newly described species Mycobacterium celatum from AIDS patients. J Clin Microbiol 1995;3(1):37-140
   Google Scholar
• Zurawski CA, Cage GD, Rimland D, Blumberg HM. Pneumonia and bacteremia due to Mycobacterium celatum masquerading as Mycobacterium xenopi in patients with AIDS: an underdiagnosed problem? Clin Infect Dis 1997;24:140-3
   PubMedGoogle Scholar
• Asiedu K, Scherpbier R, Raviglione M. Buruli ulcer. Mycobacterium ulcerans infection. Geneva: World Health Organization; 2000
   Google Scholar
• World Health Organization. Provisional guidance on the role of specific antibiotics in the management of Mycobacterium ulcerans disease (Buruli ulcer). World Health Organization, editor. Geneva: World Health Organization; 2004
   Google Scholar
• O'Brien DP, Athan E, Hughes A, Johnson PD. Successful treatment of Mycobacterium ulcerans osteomyelitis with minor surgical debridement and prolonged rifampicin and ciprofloxacin therapy: a case report. J Med Case Rep 2008;27(2):123
   Google Scholar
• Dega H, Bentoucha A, Robert J, Bactericidal activity of rifampin-amikacin against Mycobacterium ulcerans in mice. Antimicrob Agents Chemother 2002;46(10):3193-6
   PubMedGoogle Scholar
• Lefrançois S, Robert J, Chauffour A, Curing Mycobacterium ulcerans infection in mice with a combination of rifampin-streptomycin or rifampin-amikacin. Antimicrob Agents Chemother 2007;51(2):645-50
   PubMedGoogle Scholar
• Marsollier L, Honoré N, Legras P, Isolation of three Mycobacterium ulcerans strains resistant to rifampin after experimental chemotherapy of micee. Antimicrob Agents Chemother 2003;47(4):1228-32
   PubMedGoogle Scholar
• Chauty A, Ardant MF, Adeye A, Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (Mycobacterium ulcerans disease). Antimicrob Agents Chemother 2007;51(11):4029-35
   PubMedGoogle Scholar
• Etuaful S, Carbonnelle B, Grosset J, Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans. Antimicrob Agents Chemother 2005;49(8):3182-6
   PubMedGoogle Scholar
• Ji B, Chauffour A, Robert J, Jarlier V. Bactericidal and sterilizing activities of several orally administered combined regimens against Mycobacterium ulcerans in mice. Antimicrob Agents Chemother 2008;52(6):1912-6
   PubMedGoogle Scholar
• Ji B, Chauffour A, Robert J, Orally administered combined regimens for treatment of Mycobacterium ulcerans infection in mice. Antimicrob Agents Chemother 2007;51(10):3737-9
   PubMedGoogle Scholar
• Ji B, Lefrançois S, Robert J, In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans. Antimicrob Agents Chemother 2006;50(6):1921-6
   PubMedGoogle Scholar
• Johnson PD, Hayman JA, Quek TY, Consensus recommendations for the diagnosis, treatment and control of Mycobacterium ulcerans infection (Bairnsdale or Buruli ulcer) in Victoria, Australia. Med J Aust 2007;186(2):64-8
   PubMedGoogle Scholar
• De Groote MA, Huitt G. Infections due to rapidly growing mycobacteria. Clin Infect Dis 2006;42(12):1756-63
   PubMedGoogle Scholar
• Brown-Elliott BA, Wallace RJ Jr. Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria. Clin Microbiol Rev 2002;15(4):716-46
   PubMedGoogle Scholar
• Esteban J, Martín-de-Hijas NZ, Fernández AI, Epidemiology of infections due to non-pigmented rapidly growing Mycobacteria diagnosed in an urban area. Eur J Clin Microbiol Infect Dis 2008;27(10):951-7
   PubMedGoogle Scholar
• Martín-de-Hijas NZ, García-Almeida D, Ayala G, Biofilm development by clinical strains of non-pigmented rapidly growing mycobacteria. Clin Microbiol Infect 2009;15:931-6
   PubMed Web of Science ®Google Scholar
• Fernandez-Roblas R, Esteban J, Cabria F, In vitro susceptibilities of rapidly growing mycobacteria to telithromycin (HMR 3647) and seven other antimicrobials. Antimicrob Agents Chemother 2000;44(1):181-2
   PubMedGoogle Scholar
• Fernández-Roblas R, Martín-de-Hijas NZ, Fernández-Martínez AI, In vitro activity of tigecycline and 10 other antimicrobials against non-pigmented rapidly growing mycobacteria. Antimicrob Agents Chemother 2008;52(11):4184-6
   PubMedGoogle Scholar
• Wallace RJ Jr, Brown-Elliott BA, Ward SC, Activities of linezolid against rapidly growing mycobacteria. Antimicrob Agents Chemother 2001;45(3):764-7
   PubMedGoogle Scholar
• Vera-Cabrera L, Brown-Elliott BA, Wallace RJ, In vitro activities of the novel oxazolidinones DA-7867 and DA-7157 against rapidly and slowly growing mycobacteria. Antimicrob Agents Chemother 2006;50(12):4027-9
   PubMedGoogle Scholar
• Yang SC, Hsueh PR, Lai HC, High prevalence of antimicrobial resistance in rapidly growing mycobacteria in Taiwan. Antimicrob Agents Chemother 2003;47(6):1958-62
   PubMedGoogle Scholar
• Esteban J, Gadea I, Torres MV, A comparison between disk diffusion and microdilution for susceptibility testing of Mycobacterium fortuitum complex. J Chemother 2002;14(6):547-53
   PubMedGoogle Scholar
• Woods GL, Bergmann JS, Witebsky FG, Multisite reproducibility of Etest for susceptibility testing of Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum. J Clin Microbiol 2000;38(2):656-61
   PubMedGoogle Scholar
• Wallace RJ Jr, Meier A, Brown BA, Genetic basis for clarithromycin resistance among isolates of Mycobacterium chelonae and Mycobacterium abscessus. Antimicrob Agents Chemother 1996;40(7):1676-81
   PubMedGoogle Scholar
• Esteban J, Martin-de-Hijas NZ, Garcia-Almeida D, Prevalence of erm methylase genes in clinical isolates of non-pigmented, rapidly growing mycobacteria. Clin Microbiol Infect 2009;15:919-23
   PubMed Web of Science ®Google Scholar
• Esteban J, Martin-de-Hijas NZ, Ortiz-Perez A, Detection of lfrA and tap efflux pump genes among clinical iso-lates of non-pigmented rapidly growing mycobacteria. Int J Antimicrob Agents 2009;34:454-6
   PubMed Web of Science ®Google Scholar
• Nash KA, Andini N, Zhang Y, Intrinsic macrolide resistance in rapidly growing mycobacteria. Antimicrob Agents Chemother 2006;50(10):3476-8
   PubMedGoogle Scholar
• Driscoll MS, Tyring SK. Development of resistance to clarithromycin after treatment of cutaneous Mycobacterium chelonae infection. J Am Acad Dermatol 1997;36(3 Pt 1):495-6
   PubMedGoogle Scholar
• Rodriguez Diaz JC, Lopez M, Ruiz M, Royo G. In vitro activity of new fluoroquinolones and linezolid against non-tuberculous mycobacteria. Int J Antimicrob Agents 2003;21(6):585-8
   PubMedGoogle Scholar
• Wallace RJ, Brown-Elliot BA, Crist CJ, Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria. Antimicrob Agents Chemother 2002;46(10):3164-7
   PubMedGoogle Scholar
• Peres E, Khaled Y, Krijanovski OI, Mycobacterium chelonae necrotizing pneumonia after allogeneic hematopoietic stem cell transplant: report of clinical response to treatment with tigecycline. Transpl Infect Dis 2009;11(1):57-63
   PubMedGoogle Scholar
• Tam WO, Yew WW, Yam WC, Pacemaker infections due to rapidly growing mycobacteria: further experience. Int J Tuberc Lung Dis 2007;11(1):118
   PubMedGoogle Scholar
• Aubry A, Chosidow O, Caumes E, Sixty-three cases of Mycobacterium marinum infection: clinical features, treatment, and antibiotic susceptibility of causative isolates. Arch Intern Med 2002;162(15):1746-52
   PubMedGoogle Scholar
• Streit M, Böhlen LM, Hunziker T, Disseminated Mycobacterium marinum infection with extensive cutaneous eruption and bacteremia in an immunocompromised patient. Eur J Dermatol 2006;16(1):79-83
   PubMedGoogle Scholar
• Aubry A, Jarlier V, Escolano S, Antibiotic susceptibility pattern of Mycobacterium marinum. Antimicrob Agents Chemother 2000;44(11):3133-6
   PubMedGoogle Scholar
• Flynn CM, Kelley CM, Barrett MS, Jones RN. Application of the Etest to the antimicrobial susceptibility testing of Mycobacterium marinum clinical isolates. J Clin Microbiol 1997;35(8):2083-6
   PubMedGoogle Scholar
• Springer B, Wu WK, Bodmer T, Isolation and characterization of a unique group of slowly growing mycobacteria: description of Mycobacterium lentiflavum sp. nov. J Clin Microbiol 1996;34(5):1100-7
   PubMedGoogle Scholar
• Niobe SN, Bebear CM, Clerc M, Disseminated Mycobacterium lentiflavum infection in a human immunodeficiency virus-infected patient. J Clin Microbiol 2001;39(5):2030-2
   PubMedGoogle Scholar
• Tortoli E, Bartoloni A, Erba ML, Human infections due to Mycobacterium lentiflavum. J Clin Microbiol 2002;40(2):728-9
   PubMedGoogle Scholar
• Molteni C, Gazzola L, Cesari M, Mycobacterium lentiflavum infection in immunocompetent patient. Emerg Infect Dis 2005;11(1):119-22
   PubMedGoogle Scholar
• Cabria F, Torres MV, García-Cía JI, Cervical lymphadenitis caused by Mycobacterium lentiflavum. Pediatric Infect Dis J 2002;21(6):574-5
   PubMedGoogle Scholar
• Hoefsloot W, Boeree MJ, van Ingen J, The rising incidence and clinical relevance of Mycobacterium malmoense: a review of the literature. Int J Tuberc Lung Dis 2008 12(9):987-93
   PubMedGoogle Scholar
• The_Research_Committee_of_the_British_Thoracic_Society. Pulmonary disease caused by M. malmoense in HIV negative patients: 5-yr follow-up of patients receiving standardised treatment. Eur Respir J 2003;21:478-82
   PubMedGoogle Scholar
• Wayne LG, Sramek HA. Agents of newly recognized or infrequently encountered mycobacterial diseases. Clin Microbiol Rev 1992;5(1):1-25
   PubMedGoogle Scholar
• Hoffner SE, Hjelm U, Kallenium G. Susceptibility of Mycobacterium malmoense to antibacterial drugs and drug combinations. Antimicrob Agents Chemother 1993;37(6):1285-8
   PubMedGoogle Scholar
• Elsayed S, Read R. Mycobacterium haemophilum osteomyelitis: case report and review of the literature. BMC Infect Dis 2006;10(6):70
   Google Scholar
• Jarzembowski JA. Nontuberculous mycobacterial infections. Arch Pathol Lab Med 2008;132:1333-41
   PubMed Web of Science ®Google Scholar